Atara Biotherapeutics
ATRA
39 hedge funds and large institutions have $172M invested in Atara Biotherapeutics in 2014 Q4 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$61M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.9M |
| 3 |
VAM
Visium Asset Management
New York
|
+$16.9M |
| 4 |
Jennison Associates
New York
|
+$7.17M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$6.46M |
Top Sellers
ATRA Hedge Fund Activity: Q4 2014 in Review
39 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2014, worth a combined $172M.
Buyers outnumbered sellers: 39 funds opened new ATRA positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $61M.
- 39 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $172M of Atara Biotherapeutics stock for Q4 2014.
- 39 funds opened new Atara Biotherapeutics positions in Q4 2014 and 0 closed out, a net change of +39 holders.
- The largest Atara Biotherapeutics buyer in Q4 2014 was Baupost Group, an estimated $61M added.
Based on aggregated 13F filings for Q4 2014.